BioHarvest Sciences Inc. Common Stock earnings per share and revenue
On Nov 13, 2025, BHST reported earnings of -- USD per share (EPS) for Q3 25, -- the estimate of 0.02 USD, resulting in a --% surprise. Revenue reached --, compared to an expected 16.09 million, with a --% difference.
Looking ahead to Q4 25, 4 analysts forecast an EPS of 0.07 USD, with revenue projected to reach 18.76 million USD, implying an -- of --% EPS, and -- of --% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
FAQ
What were BioHarvest Sciences Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, BioHarvest Sciences Inc. Common Stock reported EPS of --, missing estimates by --, and revenue of --, -- -- expectations.
How did the market react to BioHarvest Sciences Inc. Common Stock's Q3 2025 earnings?
The stock price moved -- --, changed from -- before the earnings release to -- the day after.
When is BioHarvest Sciences Inc. Common Stock expected to report next?
The next earning report is scheduled for Mar 30, 2026.
What are the forecasts for BioHarvest Sciences Inc. Common Stock's next earnings report?
Based on 4
analysts, BioHarvest Sciences Inc. Common Stock is expected to report EPS of $0.07 and revenue of $18.76M for Q4 2025.